Triptorelin Pamoate (subcutaneous injection) for Prostate Cancer
Triptorelin is being developed as an injection under the skin (subcutaneous) for the treatment of locally advanced or metastatic prostate cancer. It is already marketed for this condition but is given by injection deep into the muscles (intramuscular). Triptorelin is an artificial analogue of natural gonadotropin‐releasing hormone that acts to slowly reduce the level of testosterone in the body. The first administration of triptorelin stimulates an increase in testosterone levels but prolonged administration leads to a fall in plasma testosterone or oestradiol to castrate levels which is maintained for as long as the product is administered. Triptorelin as a subcutaneous injection formulation has the potential advantage of improved safety and local tolerability when compared to intramuscular injection formulation.
KTE-C19 for Relapsed/Refractory B-precursor Acute Lymphocytic Leukaemia in Adults
KTE-C19 is new type of therapy where T-cells (a type of immune white blood cell) are collected from a patient and engineered to be able to recognise molecules on the surface of cancer cells, which triggers the T-cells to attack and kill the cancer cells. KTE-C19 is given to patients by a single infusion. If KTE-C19 is licenced for use in adults with refractory/relapsed acute lymphoblastic leukaemia, it will provide an additional, cancer-specific treatment option for this population who currently have limited treatment options.
Isatuximab in Addition to Pomalidomide and Dexamethasone for Relapsed and/or Refractory Multiple Myeloma
Isatuximab is in development as a treatment option for relapsed and refractory MM. It is intended to be added to pomalidomide and dexamethasone which are drugs already available to treat the condition. Isatuximab is administered intravenously as a solution concentrate and the unique way it acts may offer an additional treatment option for relapsed and refractory MM patients who have tried and failed to respond on current therapies.
Atezolizumab in Addition to Chemotherapy for Stage IV Squamous Non-Small Cell Lung Cancer – First Line
Atezolizumab is a monoclonal antibody designed to recognise and attach to a protein called ‘programmed death-ligand 1’ (PD-L1), which is present on the surface of many cancer cells. PD-L1 switches off immune cells that would otherwise attack cancer cells. By attaching to PD-L1 and reducing its effect, atezolizumab increases the ability of the immune system to attack the cancer cells and thereby slow down the progression of the disease. Atezolizumab is administered by intravenous infusion. If licensed, atezolizumab in addition to chemotherapy will offer an additional first line treatment option for patients with untreated, advanced, squamous non-small cell lung cancer.
Apalutamide in Addition to Abiraterone and Prednisone/Prednisolone for Metastatic Castration-resistant Prostate Cancer – First Line
Apalutamide is an oral tablet in development for the treatment of metastatic castration-resistant prostate cancer, when used in addition to abiraterone acetate and prednisone/prednisolone.
Apalutamide acts by blocking the androgen receptor (target binding site of various steroid hormones including testosterone) to prevent the effects of testosterone in the prostate and the body. If licensed, apalutamide in addition to abiraterone and prednisone/prednisolone will offer an additional treatment for metastatic castration-resistant prostate cancer in those who are not yet recommended to receive chemotherapy.
Ublituximab in Combination with Ibrutinib for High Risk Chronic Lymphocytic Leukaemia
The combination of ublituximab (intravenous infusions) and ibrutinib (oral capsules) is being developed as a new treatment option for patients with high risk CLL. Both drugs act in different unique ways to improve the body’s natural defence to fight the cancer cells and their combined effect may significantly reduce symptoms of the disease and increase survival. If licensed, the combination of ublituximab and ibrutinib will offer an additional treatment option for patients with high risk CLL who have received other previous treatment. This combination has the potential to improve effectiveness by offering a quicker time to response and a greater depth of response compared with ibrutinib alone.
Gilteritinib for Relapsed or Refractory Acute Myeloid Leukaemia (AML) with an FLT3 Mutation – Second Line
Gilteritinib is a drug being developed for patients with RR‐AML with FLT3 mutation. It is an inhibitor of mutant‐FLT3 enzymes and acts by blocking the production of chemicals that cause the abnormal (cancerous) white blood cells to grow. Gilteritinib is given through the oral route once a day. As there are currently limited treatment options for patients with RR‐AML that have a FLT3 mutation, gilteritinib, if licensed, has the potential to offer a new treatment option for this group of patients.
Brigatinib for locally advanced or metastatic, ALK-positive, non-small cell lung cancer – first line
Brigatinib is a new treatment option being developed specifically for ALK-positive NSCLC. It acts by blocking the activity of some specific proteins encoded by the ALK gene, thereby reducing the growth of cancer cells. Brigatinib is taken orally once daily as a tablet and potentially has a broader range of resistance when compared other treatment options in its class. Brigatinib would be offered to patients with locally advanced or metastatic ALK-positive NSCLC, who have not received prior treatment. If licensed, brigatinib will offer an additional treatment option for this patient group.
Nivolumab in addition to chemotherapy for advanced gastric cancer – first line
Nivolumab is a medicinal product that is currently licensed in the UK for the treatment of several types of advanced cancers such as melanoma, non-small cell lung cancer, and kidney cancer. It is a monoclonal antibody that acts by preventing the inhibition of T-cells (part of the body’s immune system that fight cancer) through binding to a protein called programmed cell death 1 (PD-1). Nivolumab is being developed to be used in addition to chemotherapy for the treatment of patients with advanced gastric cancer who have not had treatment previously. If licensed, nivolumab in combination with chemotherapy will offer an additional first-line treatment option for this patient group.
Elotuzumab in combination with pomalidomide and low-dose dexamethasone for relapsed and refractory multiple myeloma – third line
Elotuzumab in combination with pomalidomide and low-dose dexamethasone is in development as a treatment option for relapsed and refractory MM. Administered into the vein, elotuzumab belongs to a group of immunotherapy treatments known as monoclonal antibodies. They are designed to recognise and attach to specific proteins found more commonly on the surface of myeloma cells, enabling the immune system to target and destroy them. In combination with oral pomalidomide and low-dose dexamethasone, elotuzumab may offer an additional treatment option for relapsed and refractory MM patients who have tried and failed to respond to current therapies.